Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neovasc Sees Opportunities In Refractory Angina And Mitral Regurgitation Markets

Executive Summary

Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.

You may also be interested in...



Neovasc’s Reducer Shows Promise For Refractory Angina

In a small but sham-controlled trial Neovasc’s balloon-expandable implant significantly improved symptoms and quality of life in patients with refractory angina who are not candidates for other revascularization procedures. Reducer works by increasing pressure in the coronary sinus.

Early Experience With Neovasc’s Mitral Valve Is Encouraging; Edwards’ Disappoints

Physicians attending the EuroPCR conference in Paris heard presentations of first-in-man case studies on two new transcatheter mitral valve replacement technologies, one from Neovasc, and one from Edwards Lifesciences.

Transcatheter Mitral Valve Replacement Attracts Interest From Edwards, Others

Leading the development of transcatheter mitral valve replacement therapies is one of Edwards Lifesciences’ strategic imperatives, the company explained during its recent investor conference. The potential market is large, but so are the technical hurdles. Medtronic and other smaller players are also taking steps.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel